When was Skybound Medtech founded?

Skybound Medtech was founded in 2025 and raised its 1st funding round 1 year after it was founded.

Where is Skybound Medtech located?

Skybound Medtech is headquartered in United States.

How many employees does Skybound Medtech have?

As of Sep 30, 2026, the latest employee count at Skybound Medtech is 5.

Is Skybound Medtech a funded company?

Skybound Medtech is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Jun 08, 2026.

When was the latest funding round of Skybound Medtech?

Skybound Medtech's latest funding was a $***** Seed round on Jun 08, 2026, with participation from 0 investor.

Where does Skybound Medtech rank among its competitors?

Skybound Medtech ranks 382nd amongst 421 active competitors, of which 141 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Skybound Medtech, which secured $1.25M in Jun, 2026.

Who are the top competitors of Skybound Medtech?

Skybound Medtech's top competitors include BeiGene, Biogen and argenx. Among them, Skybound Medtech secured the most recent funding round in June, 2026.

Skybound Medtech - 2026 Company Profile, Funding & Competitors

Skybound Medtech is a seed company based in United States, founded in 2025. It operates as a Developer of medical technologies addressing physiological degradation in extreme environments. Skybound Medtech has raised $1.25M in funding. The company has 421 active competitors, including 141 funded and 115 that have exited. Its top competitors include companies like BeiGene, Biogen and argenx.

Company Details

Developer of medical technologies addressing physiological degradation in extreme environments. These platforms target musculoskeletal, neuro-ocular, immune, and genomic health challenges caused by exposure to microgravity and radiation. The technology portfolio focuses on autonomous healthcare, longevity, and personalized medicine to stabilize human health. These systems are designed for application in space exploration, national defense, and clinical settings.

Key Metrics

Founded Year

2025

Location

United States

Stage

Seed

Total Funding

$1.25M in 1 round

Latest Funding Round

Seed, Jun 08, 2026, $*****

Ranked

382^nd among 421 active competitors

Employee Count

5 as on Sep 30, 2026

Similar Companies

BeiGene & 491 more

View Skybound Medtech's full profile

Skybound Medtech has raised a total funding of $1.25M over 1 round.

Here is the list of recent funding rounds of Skybound Medtech:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 08, 2026	4124610	Seed	4488417	2981911	8373626	7706149

Access funding benchmarks and valuations. Sign up today!

View details of Skybound Medtech's funding rounds and investors

Skybound Medtech's employee count trend

Skybound Medtech has 5 employees as of Sep 26. Here is Skybound Medtech's employee count trend over the years:

Employee count trend for Skybound Medtech

Uncover Skybound Medtech's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Skybound Medtech include BeiGene, Biogen and argenx. Here is the list of Top 10 competitors of Skybound Medtech, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
4th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
5th	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	71/100
6th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	69/100
7th	Immunocore 2008, Abingdon (United Kingdom), Public	Developer of bispecific T cell receptor therapies for human diseases	$601M	General Atlantic, BlackRock & 50 others	69/100
8th	ADMA Biologics 2005, Ramsey (United States), Public	Biopharmaceutical company innovating plasma-derived therapeutics for immune deficiencies and infectious diseases	$17.6M	Aisling Capital, Burrill and Company & 4 others	68/100
9th	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100
10th	DBV Technologies 2002, Bagneux (France), Public	Developer of products for the treatment of various kinds of food allergies	$68.9M	Sofinnova Partners, Lundbeck Foundation & 16 others	68/100
382nd	Skybound Medtech 2025, United States, Seed	Developer of medical technologies addressing physiological degradation in extreme environments	$1.25M	-	21/100